Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine-Reference-Cited by-同舟云学术

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine

Published:2022 Issue: Volume:3 Page:100112
ISSN:2590-2571
Container-title:Current Research in Pharmacology and Drug Discovery
language:en
Short-container-title:Current Research in Pharmacology and Drug Discovery

Author:

Luong Thu-Lan T.^ORCID,Powers Chelsea N.,Reinhardt Brian J.,Weina Peter J.

Publisher

Elsevier BV

Subject

Animal Science and Zoology,Ecology, Evolution, Behavior and Systematics

Reference47 articles.

1. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes;Bloomer;Br. J. Clin. Pharmacol.,1992

2. Overview of drug–drug interactions with SSRIs;Brown;U.S. Pharm.,2008

3. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials;Burotto;Oncol.,2015

4. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine;Charlier;Ther. Drug Monit.,2003

5. Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition;Deodhar;Pharmaceutics,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics;Metabolites;2023-05-16

2. Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo;Clinical and Translational Science;2023-04-26